Aadi Bioscience Says PRECISION1 Tumor-agnostic Trial Unlikely To Meet Regulatory Threshold To Support Accelerated Approval And Will Be Halted

An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study.  The approximately 25 patients in PRECISION1 who are still benefiting from nab-sirolimus will be eligible for transition to a planned expanded access protocol, and a complete analysis of the PRECISION1 trial will be provided at a later date.